After a surprise collapse of its takeover bid for QIAGEN N.V. (NYSE: QGEN), Thermo Fisher Scientific Inc. (NYSE: TMO) is back with a new deal in 2021. Thermo Fisher is buying Henogen S.A. from Groupe Novasep SAS for approximately EUR 725 million ($877.5 million) in cash. Based in Belgium, Henogen S.A. is a viral vector manufacturing business that provides contract manufacturing services for vaccines and therapies to biotechnology companies and large biopharma customers.
Groupe Novasep partners with a variety of industries to provide technically optimized and economical solutions for the life science industry.
Henogen has two facilities and approximately 400 employees with substantial operational and technical expertise in a broad range of viral vector classes and an estimated 2020 revenue of EUR 80 million (approximately $95 million). The company has more than 7,000 square meters of state-of-the-art clinical and commercial manufacturing capacity. Henogen will be part of the Pharma Services business within the Laboratory Products and Services Segment for Thermo Fisher.
The deal follows one of Thermo Fisher’s largest deals for Brammer Bio in 2019, according to search results in our Healthcare Deal Database. Thermo Fisher paid Ampersand Capital Partners approximately $1.7 billion for Brammer Bio, which had an estimated $250 million in revenue in 2019. The company is a contract development and manufacturing organization that provides clinical and commercial supply of vectors for in vivo gene therapy and ex vivo gene-modified cell therapy, along with analytical development and regulatory support for the pharmaceutical and biotechnology sectors. Brammer Bio was combined with Thermo Fisher’s Laboratory Products and Services Segment.
